Trevi Therapeutics, Inc. (TRVI) Revenue History
Annual and quarterly revenue from 2016 to present
TRVI Revenue Over Time (2016–2025)
TRVI Revenue Growth History
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
TRVI Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 23, 2026, Trevi Therapeutics, Inc. (TRVI) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
TRVI's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including IDYA (+3118.1% YoY), PTCT (-53.3% YoY), and ACAD (+9.9% YoY). Compare TRVI vs IDYA →
TRVI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TRVICurrent | $0 | - | - | - | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
TRVI Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-49,328,000 | - |
| 2024 | $0 | - | $0 | - | $-51,524,000 | - |
| 2023 | $0 | - | $0 | - | $-33,923,000 | - |
| 2022 | $0 | - | $0 | - | $-29,907,000 | - |
| 2021 | $0 | - | $0 | - | $-32,476,000 | - |
| 2020 | $0 | - | $-47,000 | - | $-32,489,000 | - |
| 2019 | $0 | - | $-39,000 | - | $-26,645,000 | - |
| 2018 | $0 | - | $-23,000 | - | $-18,408,000 | - |
| 2017 | $0 | - | $0 | - | $-8,237,000 | - |
| 2016 | $0 | - | $-4,000 | - | $-8,625,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TRVI — Frequently Asked Questions
Quick answers to the most common questions about buying TRVI stock.
Is TRVI's revenue growth accelerating or slowing?
TRVI TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TRVI's revenue history from 2016 to 2026?
Trevi Therapeutics, Inc. (TRVI) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TRVI's long-term revenue growth rate (CAGR)?
Trevi Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TRVI.
Why does TRVI's quarterly revenue fluctuate?
TRVI quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Trevi Therapeutics, Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is TRVI's revenue distributed by segment?
TRVI reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TRVI's revenue compare to industry peers?
Trevi Therapeutics, Inc. (TRVI) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.